Compare AbCellera Biologics Inc (ABCL) vs Sunrun Inc (RUN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Sunrun Inc — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while Sunrun Inc trades at $11.96 (market cap $2.91B). The key difference: Sunrun Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | RUN | |
|---|---|---|
Market Cap | $2.35B | $2.91B |
Sector | Health | Technology |
52-Week High | $8.12 | $21.41 |
52-Week Low | $2.78 | $9.07 |
Enterprise Value | $1.99B | $17.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Sunrun (RUN) trades at $12.97, up 1.81% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamental metrics with a low P/E of 6.09 and robust profitability margins, while recent news highlights the company's strategic partnership with Tesla for virtual power plants targeting AI data center demand. Cash flow trends show significant investing activity with positive net cash flow.
The outlook remains cautiously optimistic with analyst consensus at Buy (62%) and a $17.58 price target, though technical weakness and negative operating cash flow present near-term risks. The Tesla partnership offers growth potential in energy infrastructure, but execution risks and market volatility require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Sunrun Inc
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →
